Latest News
-
LTIMindtree Reports Slight Q4 Profit Dip, Optimistic About Upcoming Growth -
Axis Bank Announces Q4 Net Profit at Rs 7,599 Crore Amid Deposit Accretion Worries -
hBits Expands to Pune with CyberCity Magarpatta Acquisition, Eyes Investment Opportunities -
India's First Green Hydrogen Pilot Project Goes Live at Nathpa Jhakri -
DCB Bank Q4 Results: PAT Grew 9% To Rs 156 Cr, NII Jumps 4.5%; Dividend Declared -
RBI Halts New Customer Onboarding at Kotak Mahindra Bank Over IT Compliance -
Macrotech Developers' Annual Profit Triples Despite Q4 Dip -
DoT Engages TRAI for Equitable Satcom Spectrum Allocation Guidelines -
Axis Bank Q4 Results: Net Profit Stood At Rs 7,130 Cr, NII Grew By 11%; Rs 1/Share Dividend Declared -
Infina Finance, Kotak Bank Promoter, Donates Rs 60 Cr to BJP
For Daily Alerts
Domestic pharma shares surge on Novartis ruling
Monday's ruling comes as a setback to many renowned global pharma companies that are looking at India to boost sales.
Commenting on the ruling, DG Shah, Indian Pharmaceutical Alliance (IPA) secretary said, "This is a landmark judgement that will serve to set at rest the controversy that was raised regarding the scope of section 3(d) in the Patents Act, which is a crucial safeguard against the extension of patent monopolies of known drugs and the consequent delay in the availability of affordable generic versions."
Shares of the Sun Pharma surged more than 4% to Rs 846, Divis Labs gained 4.12%, Glenmark rose 3.87% and Aurobindo Pharma gained 2.80% on BSE at 2.30 pm IST.
GoodReturns.in
More From GoodReturns
